| 0 (0%) | 12-26 20:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.54 | 1-year : | 11.14 |
| Resists | First : | 8.17 | Second : | 9.54 |
| Pivot price | 7.54  |
|||
| Supports | First : | 7.26 | Second : | 6.71 |
| MAs | MA(5) : | 7.57  |
MA(20) : | 7.51 |
| MA(100) : | 7.57 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 51.6 |
D(3) : | 46.4 |
| RSI | RSI(14): 56.1 |
|||
| 52-week | High : | 11.31 | Low : | 6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BCRX ] has closed below upper band by 35.4%. Bollinger Bands are 27.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.7 - 7.74 | 7.74 - 7.77 |
| Low: | 7.44 - 7.48 | 7.48 - 7.52 |
| Close: | 7.57 - 7.63 | 7.63 - 7.69 |
Wed, 24 Dec 2025
TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Wed, 24 Dec 2025
BioCryst Pharmaceuticals (BCRX) Is Up 8.0% After FDA Clears First Oral HAE Prophylaxis For Children - simplywall.st
Wed, 24 Dec 2025
Price-Driven Insight from (BCRX) for Rule-Based Strategy - Stock Traders Daily
Tue, 23 Dec 2025
Alane Barnes Sells 21,773 Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
Sun, 21 Dec 2025
H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 - Yahoo Finance
Fri, 12 Dec 2025
BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 211 (M) |
| Shares Float | 181 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 101.5 (%) |
| Shares Short | 37,380 (K) |
| Shares Short P.Month | 32,470 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.85 |
| Profit Margin | -1.5 % |
| Operating Margin | 18.5 % |
| Return on Assets (ttm) | 10.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 36 % |
| Gross Profit (p.s.) | 1.94 |
| Sales Per Share | 2.84 |
| EBITDA (p.s.) | 0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 50 (M) |
| Levered Free Cash Flow | 63 (M) |
| PE Ratio | -152.61 |
| PEG Ratio | 0 |
| Price to Book value | -4.15 |
| Price to Sales | 2.67 |
| Price to Cash Flow | 32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|